{"id":"syfovre","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Intraocular inflammation"},{"rate":null,"effect":"Retinal pigment epithelium tear"}]},"_chembl":{"chemblId":"CHEMBL4298211","moleculeType":"Protein"},"_dailymed":{"setId":"b4434e61-9ec9-4e0e-bd60-45aaa0a87e64","title":"SYFOVRE (PEGCETACOPLAN) INJECTION, SOLUTION [APELLIS PHARMACEUTICALS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Syfovre (pegcetacoplan) is a 40-nucleotide RNA aptamer that directly binds to VEGF-A, preventing its interaction with VEGF receptors on endothelial cells. By blocking VEGF signaling, it reduces pathological neovascularization and vascular permeability in the eye. It is administered via intravitreal injection directly into the eye to achieve high local concentrations while minimizing systemic exposure.","oneSentence":"Syfovre is an anti-VEGF aptamer that binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth and leakage in the retina.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T06:25:11.076Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Geographic atrophy secondary to age-related macular degeneration (AMD)"}]},"trialDetails":[{"nctId":"NCT06961370","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-07-16","conditions":"Geographic Atrophy, Age-related Macular Degeneration","enrollment":132}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":30,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pegcetacoplan injection"],"phase":"marketed","status":"active","brandName":"Syfovre™","genericName":"Syfovre™","companyName":"Hoffmann-La Roche","companyId":"hoffmann-la-roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Syfovre is an anti-VEGF aptamer that binds and inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth and leakage in the retina. Used for Geographic atrophy secondary to age-related macular degeneration (AMD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}